Pediatric supratentorial ependymomas with *RELA* fusions (RELA-EP) have been identified as a unique novel tumor entity \[[@CR9], [@CR10]\]. Fusions between *C11orf95* and *RELA* pathologically activate the NFκB signaling pathway indicated by nuclear accumulation of p65-RelA. Deletions of *CDKN2A* encoding the negative cell-cycle regulator p16 have been described in a subset of supratentorial ependymomas, associated with worse outcome \[[@CR2], [@CR5], [@CR7]\]. We assessed the frequency and prognostic impact of *CDKN2A* deletions in a cohort of 54 RELA-EP in children treated according to HIT2000-E protocols (for detailed demographic information, see supplementary materials and methods and supplementary table 1).

High-resolution, genome-wide copy number profiles were generated by molecular inversion probe (MIP) assay. Chromosomal breaks were identified within the *C11orf95* and *RELA* genes corresponding to fusion transcripts (Fig. [1](#Fig1){ref-type="fig"}a, d). All cases showed pathological nuclear accumulation of p65-RelA as a hallmark of RELA-EP (Fig. [1](#Fig1){ref-type="fig"}f). Homozygous deletion (complete loss) of *CDKN2A* was detected in 9 of 54 (16.7%) cases (Fig. [1](#Fig1){ref-type="fig"}c); and 8 of these (88.9%) showed a concordant complete loss of p16 protein (Fig. [1](#Fig1){ref-type="fig"}g). In one case, few tumor cells expressed p16 protein indicating retained *CDKN2A* alleles in single cells. Fourteen cases (25.9%) harbored a hemizygous deletion of *CDKN2A.* In these, p16 protein was retained in 92.9% of cases tested---one case lacked p16 protein expression indicating the inactivation of the second allele by alternative mechanisms. Thirty-one of 54 cases (57.4%) had no deletion of *CDKN2A;* all showed p16 protein expression (Fig. [1](#Fig1){ref-type="fig"}h). Immunohistochemistry for p16, therefore, may serve as a surrogate for complete *CDKN2A* loss, but cannot differentiate between hemizygous and wild-type status. There was no statistical association between *CDKN2A* deletions and mitotic activity as previously described in *IDH*-mutant glioma \[[@CR1]\]. The presence of *CDKN2A* deletions (homo- or hemizygous) correlated with higher age at diagnosis in line with the literature \[[@CR3], [@CR5], [@CR8]\]. *CDKN2A* deletion may also occur as secondary event in tumor progression \[[@CR7]\].Fig. 1**a** Genomic copy number profile and **b** allele distribution  (MIP) of a RELA-EP showing chromothripsis of chromosome 11; **c** case with homozygous *CDKN2A* deletion; **d** case showing breaks in *C11orf95* (green bar) and *RELA* (red bar); **e** clear cell morphology; **f** nuclear p65-RelA; **g** case with homozygous *CDKN2A* deletion/loss of p16 protein (arrow, endothelial cell as internal positive control); **h** case without *CDKN2A* deletion/retained p16; **i**--**k** Kaplan--Meier analysis, impact of *CDKN2A* deletions on OS

To identify possible differences between RELA-EP with versus without *CDKN2A* deletion on the transcript level, 12 RELA-EP were analyzed by RNA sequencing for differentially expressed genes. After correction for multiple testing, five genes were found significantly downregulated including *CDKN2A* and *CDKN2B* and their neighboring gene *MTAP* (*S*-methyl-5′-thioadenosine phosphorylase) located in the deleted region. MTAP is a key enzyme in the methionine salvage pathway. Its deletion leads to dependence on the activity of the methyltransferase PRMT5 \[[@CR6]\] which can be blocked by PRMT5 inhibitors as interesting novel therapeutics in *MTAP* deleted tumors. In addition, *KIF7* (15q26) encoding a cilia-associated protein and *ZNF536* (19q12) encoding a neuronal marker were found downregulated. *GABRA2* (4p12) encoding the gamma-aminobutyric acid receptor subunit alpha-2 was found highly upregulated in *CDKN2A* deleted tumors (supplementary figure 3).

Kaplan--Meier analysis revealed a significant correlation between *CDKN2A* deletions and overall survival status (OS). Different groups were compared: (1) homozygous *CDKN2A* deletion vs. hemizygous *CDKN2A* deletion and tumors with two retained alleles (*p* = 0.009); (2) homo- or hemizygous *CDKN2A* deletions vs. tumors with two retained alleles (*p* = 0.034) and (3) all three strata separately (*p* = 0.017) (Fig. [1](#Fig1){ref-type="fig"}i--k). In contrast to Korshunov et al. \[[@CR5]\], neither homozygous nor hemizygous deletion showed prognostic relevance regarding EFS (supplementary figure 2). Predominant clear cell morphology as a histological feature was a favorable prognosticator for OS (*p* = 0.039), and high mitotic activity (\> 17 mitoses/10HPF) was a predictor for tumor relapse (*p* = 0.004) as well as OS (*p* = 0.007) (supplementary figure [1](#Fig1){ref-type="fig"}). Multivariate analysis confirmed mitotic activity as independent prognostic indicator for EFS (supplementary table 2).

Our data show that deletions of *CDKN2A* represent an objective parameter for risk stratification in RELA-EP. Molecular inversion probe methodology turned out to represent a sensitive and quantitative tool for *CDKN2A* assessment in FFPE material. Apart from ependymoma, homozygous deletions of *CDKN2A* have recently been described as adverse prognostic marker for other CNS tumors, including anaplastic *IDH*-mutant gliomas and *BRAF*-mutant low-grade gliomas \[[@CR1], [@CR4], [@CR11]\]. The deletion/inactivation of *CDKN2A* may result in a pathological activation of cyclin-dependent kinases 4/6 targetable by specific inhibitors such as palbociclib. Therefore, *CDKN2A* inactivation in RELA-ependymomas may represent a potential therapeutical target.
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